NCT00004870View on ClinicalTrials.gov

Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2000

Primary Completion Date

September 30, 2002

Study Completion Date

September 30, 2002

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

oblimersen sodium

DRUG

irinotecan hydrochloride

Trial Locations (3)

78229

San Antonio Cancer Institute, San Antonio

78234

Brooke Army Medical Center, Fort Sam Houston

44106-5065

Ireland Cancer Center, Cleveland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT00004870 - Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | Biotech Hunter | Biotech Hunter